Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: Implications for therapeutic drug monitoring

Therapeutic Drug Monitoring

Volumn 22, Issue 1, 2000, Pages 20-26

  Oellerich, Michael ^a   Shipkova, Maria ^a   Schütz, Ekkehard ^a   Wieland, Eberhard ^a   Weber, Lute ^b   Tönshoff, Burkhard ^b   Armstrong, Victor W ^a   Boswald M ^c   Ruder, H ^c   Schroder M ^c   Dippel, J ^c   Staskewitz, A ^c   Kirste, G ^c   Zimmerhackl, L B ^c   Weber, L ^c   Lamersdorf, T ^c   Tonshoff B ^c   John, U ^c   Misselwitz, J ^c   Querfeld, U ^c   Greiner, C ^c   Klaus, G ^c   Klare, B ^c   Bulla, M ^c   Holder, M ^c   Leichter, H ^c   more..

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NONE

Author keywords

Mycophenolic acid; Pediatric renal transplants

Indexed keywords

MYCOPHENOLIC ACID;

AREA UNDER THE CURVE; ARTICLE; DISEASE ASSOCIATION; DRUG METABOLISM; DRUG MONITORING; GRAFT REJECTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY TRANSPLANTATION; PRIORITY JOURNAL; RISK ASSESSMENT;

CHILD; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID;

EID: 12944260647     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200002000-00004     Document Type: Article

References (21)

1. Shaw LM, Nicholls A, Hale M, et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998; 31:317-22.
2. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55.
3. Weber LT, Shipkova M, Lamersdorf T, et al. Pharmacokinetics of mycophenolic acid (MPA) and determinants of MPA free fraction in pediatric and adult renal transplant recipients. German Study group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. J Am Soc Nephrol 1998;9:1511-20.
4. Weber LT, Lamersdorf T, Shipkova M, et al. The area under the plasma concentration-time curve for total but not for free mycophenolic acid increases in the stable phase post renal transplantation: a longitudinal study in pediatric patients. Ther Drug Monit 1999:21:498-506.
5. Hale MD, Nicholls AJ, Bullingham RE, et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation, clin Pharmacol Ther 1998;64:672-83.
6. Takahashi K, Ochiai T, Uchida K, et al. Pilot study of mycophenolate mofetil (RS-61443) in the prevention of acute rejection following renal transplantation in Japanese patients. RS-61443 Investigation Committee-Japan. Transplant Proc 1995;27:1421-4.
7. Shaw LM, Nowak I. Mycophenolic acid: measurement and relationship to pharmacologic effects. Ther Drug Monit 1995;17: 685-9.
8. Tsina I, Kaloostian M, Lee R, Tarnowski T, Wong B. High-performance liquid Chromatographic method for the determination of mycophenolate mofetil in human plasma. J Chromatogr B Biomed Appl 1996;681:347-53.
9. Shipkova M, Niedmann PD, Armstrong VW, et al. Simultaneous determination of mycophenolic acid and its glucuronide in human plasma using a simple high-performance liquid chromatography procedure. Clin Chem 1998;44:1481-8.
10. Schutz E, Shipkova M, Armstrong VW, et al. Therapeutic drug monitoring of mycophenolic acid: comparison of HPLC and immunoassay reveals new MPA metabolites. Transplant Proc 1998; 30:1185-7.
11. Beal JL, Jones CE, Taylor PJ, Tett SE. Evaluation of an immunoassay (EMIT) for mycophenolic acid in plasma from renal transplant recipients compared with a high-performance liquid chromatography assay. Ther Drug Monit 1998;20:685-90.
12. Schutz E, Shipkova M, Armstrong VW, Wieland E, Oellerich M. Identification of a pharmacologically active metabolite of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Clin Chem 1999;45:419-22.
13. Shipkova M, Armstrong VW, Wieland E, et al. Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil. Br J Pharmacol 1999;126:1075-82.
14. Shipkova M, Schutz E, Armstrong VW, Niedmann PD, Wieland E, Oellerich M. Overestimation of mycophenolic acid by EMIT correlates with MPA metabolite. Transplant Proc 1999;31:1135-7.
15. Nicholls AJ. Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection. Clin Biochem 1998;31:329-33.
16. Shaw LM, Mick R, Nowak I, Korecka M, Bray man KL. Pharmacokinetics of mycophenolic acid in renal transplant patients with delayed graft function. J Clin Pharmacol 1998;38:268-75.
17. Kaplan B, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. Transplantation 1998;65:1127-9.
18. Schutz E, Armstrong VW, Shipkova M, et al. Limited sampling strategy for the determination of mycophenolic acid area under the curve in pediatric kidney recipients. German Study Group on MMF Therapy in Pediatric Renal Transplant Recipients. Transplant Proc 1998;30:1182-4.
19. Zanker B, Schneeberger H, Rothenpieler U, et al. Mycophenolate mofetil-based, cyclosporine-free induction and maintenance immunosuppression: first-3-months analysis of efficacy and safety in two cohorts of renal allograft recipients. Transplantation 1998;66: 44-9.
20. Meiser BM, Pfeiffer M, Schmidt D, et al. Combination therapy with tacrolimus and mycophenolate mofetil following cardiac transplantation: importance of mycophenolic acid therapeutic drug monitoring. J Heart Lung Transplant 1999;18:143-9.
21. Mathew TH. A blinded, long-term, randomized multicenter study of mycophenolate mofetil in cadaveric renal transplantation: results at three years. Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group. Transplantation 1998;65:1450-4.